Exozymes Inc. (EXOZ) stock
EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.43+0.12 (+3.63%)
Close on Nov 18, 2026Market cap $31.84MP/E –Yield –
Exozymes operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Exozymes's operating income for the twelve months ending Sep 30, 2026 was -$11.08M. For fiscal 2025 it was -$9.72M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.72M | – |
| FY2024 | Dec 31, 2024 | -$5.93M | – |
| FY2023 | Dec 31, 2023 | -$1.80M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.05M | – |
| Q2 FY2026 | Jun 30, 2026 | -$2.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.39M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.55M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.95M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$985.05K | – |
| Q3 FY2023 | Sep 30, 2023 | -$391.85K | – |
See a number that looks wrong?